Synopsis
Synopsis
0
VMF
0
Canada
DRUG PRODUCT COMPOSITIONS
0
Weekly News Recap #Phispers
1. 4-methyl-n-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
2. Amn 107
3. Amn-107
4. Amn107
5. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride (1:1)
6. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride, Hydrate
7. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride, Hydrate (1:1:2)
8. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride, Hydrate (1:2:2)
9. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride, Hydrate (2:2:3)
10. Nilotinib
11. Nilotinib Dihydrochloride Dihydrate
12. Nilotinib Hydrochloride Anhydrous
13. Nilotinib Hydrochloride Dihydrate
14. Nilotinib Hydrochloride Hydrate
15. Nilotinib Hydrochloride Monohydrate
16. Nilotinib Hydrochloride Sesquihydrate
17. Tasigna
1. 923288-95-3
2. Nilotinib Hydrochloride Anhydrous
3. Nilotinib Hcl
4. 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide Hydrochloride
5. Nilotinib (hydrochloride)
6. K37n7byx3x
7. 4-methyl-n-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide;hydrochloride
8. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride (1:1)
9. Nilotinib (as Hydrochloride)
10. Unii-k37n7byx3x
11. Amn 107 Hydrochloride
12. Amn-107 Hcl
13. Schembl434496
14. Dtxsid60238968
15. Bcp29532
16. Hy-10159b
17. S5205
18. Ccg-270077
19. Nilotinib Hydrochloride [vandf]
20. Bn164657
21. Nilotinib Hydrochloride Monohydrate- Bio-x
22. Cs-0085192
23. Nilotinib Hydrochloride [orange Book]
24. Nilotinib Hydrochloride Anhydrous [who-dd]
25. Q27281888
26. Nilotinib Hcl;amn 107; Amn107; Amn-107; Nilotinib Hydrochloride Anhydrous
27. 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamidehydrochloride
28. 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide Hydrochloride
29. 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide Hydrochloride
Molecular Weight | 566.0 g/mol |
---|---|
Molecular Formula | C28H23ClF3N7O |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 6 |
Exact Mass | 565.1604706 g/mol |
Monoisotopic Mass | 565.1604706 g/mol |
Topological Polar Surface Area | 97.6 Ų |
Heavy Atom Count | 40 |
Formal Charge | 0 |
Complexity | 817 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
94
PharmaCompass offers a list of Nilotinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Nilotinib manufacturer or Nilotinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Nilotinib manufacturer or Nilotinib supplier.
PharmaCompass also assists you with knowing the Nilotinib API Price utilized in the formulation of products. Nilotinib API Price is not always fixed or binding as the Nilotinib Price is obtained through a variety of data sources. The Nilotinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Nilotinib Fumarate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nilotinib Fumarate, including repackagers and relabelers. The FDA regulates Nilotinib Fumarate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nilotinib Fumarate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nilotinib Fumarate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nilotinib Fumarate supplier is an individual or a company that provides Nilotinib Fumarate active pharmaceutical ingredient (API) or Nilotinib Fumarate finished formulations upon request. The Nilotinib Fumarate suppliers may include Nilotinib Fumarate API manufacturers, exporters, distributors and traders.
click here to find a list of Nilotinib Fumarate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nilotinib Fumarate DMF (Drug Master File) is a document detailing the whole manufacturing process of Nilotinib Fumarate active pharmaceutical ingredient (API) in detail. Different forms of Nilotinib Fumarate DMFs exist exist since differing nations have different regulations, such as Nilotinib Fumarate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nilotinib Fumarate DMF submitted to regulatory agencies in the US is known as a USDMF. Nilotinib Fumarate USDMF includes data on Nilotinib Fumarate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nilotinib Fumarate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nilotinib Fumarate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Nilotinib Fumarate Drug Master File in Japan (Nilotinib Fumarate JDMF) empowers Nilotinib Fumarate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Nilotinib Fumarate JDMF during the approval evaluation for pharmaceutical products. At the time of Nilotinib Fumarate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Nilotinib Fumarate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Nilotinib Fumarate Drug Master File in Korea (Nilotinib Fumarate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Nilotinib Fumarate. The MFDS reviews the Nilotinib Fumarate KDMF as part of the drug registration process and uses the information provided in the Nilotinib Fumarate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Nilotinib Fumarate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Nilotinib Fumarate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Nilotinib Fumarate suppliers with KDMF on PharmaCompass.
A Nilotinib Fumarate CEP of the European Pharmacopoeia monograph is often referred to as a Nilotinib Fumarate Certificate of Suitability (COS). The purpose of a Nilotinib Fumarate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Nilotinib Fumarate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Nilotinib Fumarate to their clients by showing that a Nilotinib Fumarate CEP has been issued for it. The manufacturer submits a Nilotinib Fumarate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Nilotinib Fumarate CEP holder for the record. Additionally, the data presented in the Nilotinib Fumarate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Nilotinib Fumarate DMF.
A Nilotinib Fumarate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Nilotinib Fumarate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Nilotinib Fumarate suppliers with CEP (COS) on PharmaCompass.
A Nilotinib Fumarate written confirmation (Nilotinib Fumarate WC) is an official document issued by a regulatory agency to a Nilotinib Fumarate manufacturer, verifying that the manufacturing facility of a Nilotinib Fumarate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nilotinib Fumarate APIs or Nilotinib Fumarate finished pharmaceutical products to another nation, regulatory agencies frequently require a Nilotinib Fumarate WC (written confirmation) as part of the regulatory process.
click here to find a list of Nilotinib Fumarate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nilotinib Fumarate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nilotinib Fumarate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nilotinib Fumarate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nilotinib Fumarate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nilotinib Fumarate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nilotinib Fumarate suppliers with NDC on PharmaCompass.
Nilotinib Fumarate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nilotinib Fumarate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nilotinib Fumarate GMP manufacturer or Nilotinib Fumarate GMP API supplier for your needs.
A Nilotinib Fumarate CoA (Certificate of Analysis) is a formal document that attests to Nilotinib Fumarate's compliance with Nilotinib Fumarate specifications and serves as a tool for batch-level quality control.
Nilotinib Fumarate CoA mostly includes findings from lab analyses of a specific batch. For each Nilotinib Fumarate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nilotinib Fumarate may be tested according to a variety of international standards, such as European Pharmacopoeia (Nilotinib Fumarate EP), Nilotinib Fumarate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nilotinib Fumarate USP).